Catalyst Wire Dossier Catalyst Wire Dossier

RSVPreF3 OA

RSV prefusion F protein vaccine for older adults · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for RSVPreF3 OA, covering 2022-06-29 to 2025-05-18. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults [Phase 3]

See pricing